<DOC>
	<DOC>NCT00364845</DOC>
	<brief_summary>Treatment of anemia associated with chronic kidney disease (CKD) during 36 weeks with safety follow up phase of 52 weeks</brief_summary>
	<brief_title>STIMULATE Study: Anemia Correction and Health-related Quality of Life (HRQoL) Outcomes in Elderly Chronic Kidney Disease (CKD) Patients</brief_title>
	<detailed_description>This is a multicentre, randomised, single-blind, placebo-controlled, two-arm parallel group study assessing the effect of anaemia correction and Hb maintenance with darbepoetin alfa in elderly CKD patients for 36 weeks.</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Stage 35 CKD not on dialysis Patients ≥ 70 years of age Haemoglobin &lt; 110g/L at screening Transferrin saturation ≥ 15% at screening Clinical history of type 2 diabetes mellitus Anticipating or scheduled to go on renal replacement therapy in the next year, including renal transplant Uncontrolled hypertension on two separate measurements during screening Use of any erythropoietic protein within 12 weeks of screening</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Quality of Life</keyword>
	<keyword>Chronic Kidney Disease</keyword>
	<keyword>Anemia</keyword>
</DOC>